LEADERS FREE II: BioFreedom™ Pivotal Study
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
Summary
- Conditions
- Acute Coronary Syndrome
- High Bleeding Risk
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
In this study all patients will receive the BioFreedom™ Drug Coated Stent and one month of Dual Anti Platelet Therapy
In this study all patients will receive the BioFreedom™ Drug Coated Stent and one month of Dual Anti Platelet Therapy
Tracking Information
- NCT #
- NCT02843633
- Collaborators
- Not Provided
- Investigators
- Study Chair: Martin Leon Cardiovascular Research Foundation, New York Principal Investigator: Mitchell Krucoff Duke University Principal Investigator: Philip Urban Hôpital de la Tour
Get Well Soon